CORALreef OUTCOMES
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
- Stadium
- followup
- Middel
- enlicitide (oraal PCSK9-i)
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 10 juni 2024
- Last Patient In
- 24 juli 2025
- Last Patient Last Visit
- 1 november 2029
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Studiedirecteur
dr. L. Kleijn
Cardioloog
Contact Kantoor
